Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study-Reference-Cited by-同舟云学术

Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study

Published:2024-08 Issue:8 Volume:9 Page:718-733
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Janssen Harry L A,Lim Young-Suk,Lampertico Pietro,Heo Jeong,Chen Chi-Yi,Fournier Claire,Tsang Tak Yin Owen,Bae Ho,Chen Chien-Hung,Coffin Carla S,Ahn Sang Hoon,Trinh Huy,Flaherty John F,Abramov Frida,Zhao Yang,Liu Yang,Lau Audrey,German Polina,Chuang Wan-Long,Agarwal Kosh,Gane Edward

Funder

Gilead Sciences Inc

Publisher

Elsevier BV

Reference29 articles.

1. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection;Lampertico;J Hepatol,2017

2. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance;Terrault;Hepatology,2018

3. Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients;Lampertico;Aliment Pharmacol Ther,2016

4. An aging population of chronic hepatitis B with increasing comorbidities: a territory-wide study from 2000–2017;Wong;Hepatology,2020

5. Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy;Murakami;Antimicrob Agents Chemother,2015

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Broadening clinical indications of tenofovir alafenamide in chronic hepatitis B;The Lancet Gastroenterology & Hepatology;2024-08